Commensal Bacteroidetes protect against Klebsiella pneumoniae colonization and transmission through IL-36 signalling by Sequeira, Richard P. et al.
 1 
Commensal Bacteroidetes protect against Klebsiella pneumoniae 1 
colonization and transmission through IL-36 signalling 2 
 3 
Richard P. Sequeira1, Julie A. K. McDonald2, Julian R. Marchesi2,3, and Thomas B. Clarke1* 4 
 5 
1MRC Centre for Molecular Bacteriology and Infection, Department of Infectious Diseases, Imperial 6 
College London, London, SW7 2AZ, UK. 7 
 8 
2Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer, 9 
Imperial College London, London, SW7 2AZ, UK. 10 
 11 
3School of Biosciences, Cardiff University, Cardiff, CF10 3AX, UK.  12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
*Lead author and correspondence: 24 
 25 
Thomas.Clarke@imperial.ac.uk 26 
 2 
The microbiota primes immune defences but the identity of specific commensal microbes which 1 
protect against infection is unclear. Conversely, how pathogens compete with the microbiota to 2 
establish their host niche is also poorly understood. Here, we investigate the antagonism 3 
between the microbiota and Klebsiella pneumoniae during colonization and transmission. We 4 
discover that maturation of the microbiota drives the development of distinct immune defence 5 
programs in the upper airway and intestine to limit K. pneumoniae colonization within these 6 
niches. Immune protection in the intestine depends on the development of Bacteroidetes, IL-36 7 
signalling and macrophages. This effect of Bacteroidetes requires their conserved commensal 8 
colonization factor (CCF) polysaccharide utilization locus. Conversely, in the upper airway, 9 
Proteobacteria prime immunity through IL-17A, but K. pneumoniae overcomes these defences 10 
through encapsulation to effectively colonize this site. Ultimately, we find that host-to-host 11 
spread of K. pneumoniae occurs principally from its intestinal reservoir, and that CCF-producing 12 
Bacteroidetes are sufficient to prevent transmission between hosts through IL-36. Thus, our 13 
study provides mechanistic insight into when, where and how commensal Bacteroidetes protect 14 
against K. pneumoniae colonization and contagion, providing insight into how these protective 15 
microbes could be harnessed to confer population-level protection against K. pneumoniae 16 
infection.  17 
 18 
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INTRODUCTION 1 
 2 
The microbiota enhances immune defences to protect against pathogenic microbes1-4. Identifying 3 
members of the microbiota that protect against pathogens could therefore provide an alternative means 4 
to treat infections resistant to current antimicrobial therapies5. Of these antimicrobial resistant 5 
organisms, it is bacteria from the Enterobacteriaceae family which are the greatest clinical problem6-9. 6 
Within this family, K. pneumoniae are the most urgent threat to human health because many strains are 7 
resistant to multiple antibiotics, are highly virulent, cause disease in both adults and infants, and readily 8 
spreading between hosts8,10-14. 9 
 10 
Asymptomatic colonization is the pivotal step in K. pneumoniae pathogenesis as this serves as the 11 
reservoir of organisms which initiate acute infection and is also the source of organisms which transmit 12 
to other hosts10-13,15,16. K. pneumoniae is a versatile colonizer with two principal niches within the human 13 
host: the upper airway and intestine11,13,15,17,18. To establish colonization K. pneumoniae must therefore 14 
contend with defences established by the microbiota and immune system at both of these sites. Clinical 15 
data confirm the importance of the microbiota and immune system in resisting the establishment of K. 16 
pneumoniae colonization. Specifically, the association between patients receiving antibiotics and 17 
increased incidence of K. pneumoniae colonization10,19; the demonstration that microbiota 18 
transplantation, in humans and mice, clears K. pneumoniae from the intestine20-24; and the association 19 
between immunosuppression and increased risk of K. pneumoniae colonization25-27 highlight the critical 20 
role of the microbiota and immune system in protecting against K. pneumoniae colonization. The 21 
mechanistic basis for this protection, and whether there is collaboration between these microbial and 22 
immune defences system, is poorly understood hampering the use of microbiota-based approaches to 23 
protect against K. pneumoniae.  24 
 25 
Once colonization has been established, these hosts serve as reservoirs for the transmission of K. 26 
pneumoniae within a population. The process of transmission involves exiting the colonized host, 27 
 4 
surviving in the environment, acquisition by a new host, and then successful reestablishment of 1 
colonization at a new mucosal site. Although the importance of K. pneumoniae transmission is 2 
undoubted, and has underpinned its success as a pathogen, the host and bacterial factors dictating the 3 
outcome of transmission are poorly defined. Here, by analysing the development of microbiota-mediated 4 
defences in the upper airway and intestine, we reveal the commensal taxa that inhibit K. pneumoniae 5 
colonization and transmission, the immunological basis for their protection, and the countervailing tactics 6 
used by K. pneumoniae to establish colonization in the face of these defences. Through this fundamental 7 
analysis, we define a simple consortium of commensal microbes which prevent the host-to-host spread 8 
of this contagious pathogen.  9 
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RESULTS 1 
 2 
The development of the adult microbiota protects against colonization by antibiotic-resistant 3 
Klebsiella pneumoniae in the intestine but not upper airway 4 
 5 
As K. pneumoniae causes disease in infants and adults, we wanted to investigate the development of 6 
microbiota-mediated defences against K. pneumoniae colonization across lifecourse. To do this, we 7 
depleted the microbiota in neonatal and adult mice (Supplementary Fig. 1a-e). To study upper airway 8 
colonization by K. pneumoniae, we used a small inoculation volume and did not anaesthetize mice for 9 
intranasal inoculation. This approach means bacteria remain in the nasal cavities and nasopharynx and 10 
do not reach the lung28,29 (Supplementary Fig. 2). In neonates, K. pneumoniae was able to colonize 11 
both the upper airway and intestine and this unaffected by microbiota-depletion (Fig. 1a-c). Likewise, in 12 
the adult upper airway, K. pneumoniae colonization levels were similar between control and microbiota-13 
depleted animals (Fig. 1d-f). In the adult intestine, by contrast, K. pneumoniae could only establish 14 
detectable colonization after microbiota-depletion (Fig. 1g-j). Sustained broad spectrum antibiotic 15 
treatment (Fig. 1g-j), or a short, clinically-relevant antibiotic regimen (Supplementary Fig. 3a,b) 16 
eliminated microbiota-mediated defences. Transferring the adult, but not the neonatal microbiota to 17 
neonatal mice protected against intestinal colonization by K. pneumoniae (Fig. 1k-m). The adult 18 
intestinal microbiota was broadly protective, inhibiting colonization by clinical isolates of K. pneumoniae 19 
producing the OXA-48 carbapenenemase (Fig. 1g), the pandemic K. pneumoniae ST258 (Fig. 1l), and 20 
closely related K. quasipneumoniae subsp. similipneumoniae (Fig. 1j). No weight loss was observed 21 
during colonization of either niche (Supplementary Fig. 4a,b) supporting the notion that we were 22 
modelling asymptomatic colonization. These data show that the development of the adult microbiota 23 
creates a barrier sufficient to block K. pneumoniae colonization in the intestine but not the upper airway. 24 
This raised three questions: (i) which members of the adult intestinal microbiota prevent K. pneumoniae 25 
colonization, and by what mechanism? (ii) What factors allow K. pneumoniae to successfully compete 26 
with the upper airway microbiota to colonize this niche? And, most critically, (iii) how does this 27 
 6 
competition between the microbiota and K. pneumoniae at different mucosal reservoirs impact the host-1 
to-host spread of this contagious pathogen? 2 
 3 
The development of Bacteroidetes prevents Klebsiella pneumoniae intestinal colonization  4 
 5 
To answer our first question, we sequenced the neonatal and adult mouse intestinal microbiota to 6 
determine the respective composition of these permissive and inhibitory microbial communities. The 7 
neonatal intestinal microbiota was dominated by bacteria from the Firmicutes phylum, and specifically 8 
members of the Lactobacillales order (Fig. 2a,b). The adult intestinal microbiota, by contrast, was 9 
composed predominately of commensals from the Bacteroidetes (Bacteroidales) and Firmicutes 10 
(Clostridia and Lactobacillales) phyla, with Actinobacteria and Proteobacteria comprising a minor 11 
fraction of the commensal taxa present (Fig. 2a,b). We therefore used defined consortia of commensals 12 
to determine whether the development of Bacteroidetes, non-Lactobacillales Firmicutes, Actinobacteria, 13 
or Proteobacteria drove resistance to intestinal colonization by K. pneumoniae. We found that only 14 
Bacteroidetes promoted clearance of K. pneumoniae from the intestine, whether administered before or 15 
after the establishment of K. pneumoniae colonization (Fig. 2c-k). Bacteroidetes were protective in both 16 
antibiotic treated (Fig. 2d-f,i,j) and germ-free mice (Fig. 2g) and this was consistent using commensal 17 
consortia of different compositions (Extended Data Fig. 1). We verified the intestinal microbiota of mice 18 
administered our representative commensal consortia was dominated by that consortium and that 19 
colonization levels of each consortia were similar (Extended Data Fig. 2). Additionally, we found that 20 
Bacteroidetes specifically protected against intestinal colonization by K. pneumoniae in neonates (Fig. 21 
2k), supporting the idea that it is the development of this commensal phylum that protects against K. 22 
pneumoniae in adults.  23 
 24 
CCF-producing Bacteroidetes fortifies the intestinal immune barrier via IL-36 and macrophages 25 
to prevent Klebsiella pneumoniae intestinal colonization  26 
 27 
 7 
Next, we wanted to determine whether the protective effect of Bacteroidetes required host immunity. 1 
We therefore transferred the microbiota to microbiota-depleted mice administered the 2 
immunosuppressive dexamethasone, or vehicle control, prior to K. pneumoniae colonization. 3 
Dexamethasone eliminated the inhibitory effect of the microbiota on K. pneumoniae colonization 4 
(Extended Data Fig. 3a,b), indicating that protection required immune signalling. Furthermore, we 5 
found that dexamethasone treatment of non-antibiotic treated mice made these normally resistant mice 6 
susceptible to colonization by K. pneumoniae (Extended Data Fig. 3c-e). Similarly, we found that 7 
protection conferred by Bacteroidetes required immune signalling (Extended Data Fig. 3f,g). To ensure 8 
that dexamethasone was acting on the immune system rather than disrupting the microbiota, we 9 
transferred the microbiota from dexamethasone or vehicle control treated mice, to microbiota-depleted 10 
mice and then examined the inhibitory effect on K. pneumoniae colonization. Both of these microbiota 11 
provided equivalent protection against K. pneumoniae colonization (Supplementary Fig. 5), 12 
demonstrating that dexamethasone does not eliminate protective commensals from the microbiota but 13 
instead inhibits the stimulatory effect of the microbiota on the immune system. Next, we sought to 14 
determine the immune factors which translate the effect of Bacteroidetes into resistance against K. 15 
pneumoniae colonization. In the intestine, the transition from neonate to adult was marked by the 16 
increased homeostatic expression of a number of cytokines important in maintaining host-microbial 17 
homeostasis (Supplementary Fig. 6). To determine whether the protective effect of Bacteroidetes was 18 
driven by these cytokine, we abrogated the signalling of cytokines whose homeostatic expression 19 
increased from neonates to adults in a microbiota-dependent manner. Protection against intestinal 20 
colonization by K. pneumoniae by Bacteroidetes was abrogated after treatment with an antibody 21 
targeting the IL-36 receptor signalling, but not IL-17A or IFNg, (Fig. 3a-e). Supporting the role of IL-36, 22 
we found that treatment with recombinant IL-36g promoted clearance of intestinal K. pneumoniae (Fig. 23 
3f-h) and that intestinal IL-36g production in microbiota-depleted animals was specifically restored by 24 
Bacteroidetes (Fig. 3i). Within the intestine, macrophages act as a critical innate interface with the 25 
microbiota, so we therefore investigated their role in protection against K. pneumoniae using liposome 26 
clodronate treatment to deplete these cells (Supplementary Fig. 7). After macrophage depletion, 27 
 8 
Bacteroidetes could not protect against K. pneumoniae, or regulate IL-36g (Fig. 3j-m). By contrast 1 
Bacteroidetes were still protective after neutrophil depletion (Supplementary Fig. 8). Furthermore, in 2 
clodronate treated mice, disruption of IL-36R signalling did not increase K. pneumoniae colonization, 3 
suggesting that IL-36 and macrophages work along a common pathway (Fig. 3n). To understand how 4 
IL-36 controls K. pneumoniae levels in the intestine via macrophages, we investigated if IL-36 promotes 5 
the bactericidal activity of these cells. We found that IL-36g stimulation promoted the killing of multiple 6 
strains of K. pneumoniae by macrophages (Extended Data Fig. 4a-d). Next, we wanted to understand 7 
the factors in Bacteroidetes required for protection against K. pneumoniae colonization. Common 8 
amongst commensals that regulate intestinal immunity is a requirement for intimate contact with the 9 
host mucosa to exert their effects30. Highly conserved within Bacteroidetes is a capsular polysaccharide 10 
production locus, the commensal colonization factors (CCF), which promote the association of 11 
Bacteroidetes with the intestinal mucosa31,32. We tested the hypothesis that CCFs are required for 12 
Bacteroidetes to inhibit K. pneumoniae colonization. In agreement with this, a consortium of 13 
Bacteroidetes, or a single Bacteroidetes species, was able to protect against K. pneumoniae 14 
colonization and prime intestinal IL-36g production with an intact CCF system, but this was lost in the 15 
absence of CCFs, and could be reestablished by complementation of the CCFs (Fig. 4a-g). In line with 16 
their proposed role in mucosal colonization, we found that the CCFs promoted the association of 17 
Bacteroidetes with the mucosa (Fig. 4h), but fecal levels of Bacteroidetes were equivalent in the 18 
presence or absence of CCFs (Fig. 4i). Together, our data support a model whereby CCF-producing 19 
Bacteroidetes associate with the mucosal barrier to create an immune barrier within the intestine 20 
preventing colonization by K. pneumoniae through IL-36 and macrophages.  21 
 22 
The adult microbiota primes upper airway defences through IL-17A, but encapsulation allows 23 
Klebsiella pneumoniae to overcome this barrier to establish colonization 24 
 25 
We then wanted to answer our second question: what factors allow K. pneumoniae to successfully 26 
compete with the upper airway microbiota to colonize this niche? To do this, we examined the role of K. 27 
 9 
pneumoniae encapsulation. Traditionally, encapsulation has been viewed as a virulence determinant, 1 
however, capsular polysaccharide production is common to both pathogens and non-pathogens, 2 
especially in the upper airway33. In adult mice with a microbiota, we found that encapsulated K. 3 
pneumoniae colonized the upper airway higher levels than an isogenic unencapsulated K. pneumoniae 4 
mutant34 and the ability to withstand microbiota-mediated defences was restored by complementation 5 
of the unencapsulated mutant (Fig. 5a,b). This advantage of encapsulation was lost in microbiota-6 
depleted animals, where encapsulated and unencapsulated K. pneumoniae colonized to similar levels 7 
(Fig. 5a,b). Next, therefore, we determined whether encapsulation allows K. pneumoniae to withstand 8 
direct microbial competition within the upper airway, or indirect effects of the microbiota via the immune 9 
system. To address this, we transferred the microbiota back to microbiota-depleted animals treated with 10 
dexamethasone or vehicle control, prior to intranasal administration of K. pneumoniae. Microbiota 11 
transfer reduced upper airway colonization by unencapsulated K. pneumoniae in vehicle control (Fig. 12 
5a,b), but not dexamethasone treated animals (Fig. 5a,b), supporting the notion that the microbiota 13 
enhances defences in the upper airway via immune signalling. In agreement with this, innate cytokine 14 
production (TNFa), which is induced by K. pneumoniae during upper airway colonization, was reduced 15 
in microbiota-depleted animals, and restored by microbiota transfer through immune signalling 16 
(Extended Data Fig. 5a,b). We confirmed that levels of upper airway commensal bacteria after 17 
microbiota transfer were equivalent between vehicle and dexamethasone treated mice (Extended Data 18 
Fig. 5c) and that microbiota transfer did not result in commensal inoculation into the lung (Extended 19 
Data Fig. 6a). Analogously to the intestine, microbiota priming of immune defences in the upper airway 20 
was specific to adult animals, as encapsulated and unencapsulated K. pneumoniae colonized the 21 
neonatal upper airway to similar levels and induced an equivalent innate cytokine response in 22 
microbiota-depleted and control animals (Extended Data Fig. 7a,b). The transition from neonate to 23 
adult was accompanied by the increased homeostatic expression of a number of cytokines in the upper 24 
airway which were dependent on the microbiota (Supplementary Fig. 9). We therefore abrogated 25 
signalling by these cytokines to understand if they were required for the adult microbiota to exert its 26 
immunomodulatory effects in the upper airway. Disruption of IL-17A, but not IFNg or IL-36R signalling, 27 
 10 
inhibited microbiota-mediated clearance of unencapsulated, but not encapsulated, K. pneumoniae from 1 
the upper airway (Fig. 5c-f). Furthermore, treatment with recombinant IL-17A was sufficient to promote 2 
clearance of unencapsulated K. pneumoniae (Fig. 5g,h). The upper airway microbiota of mice 3 
comprises bacteria from the Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria phyla 4 
(Extended Data Fig. 6b)35-41. Of these commensals, we found that Proteobacteria specifically enhanced 5 
clearance of unencapsulated K. pneumoniae from the upper airway in antibiotic treated and germ-free 6 
mice by IL-17A signalling (Fig. 5i-l). Proteobacteria also restored homeostatic IL-17A production in the 7 
upper airway and cytokine production induced by K. pneumoniae colonization (Extended Data Fig. 8a-8 
c). We verified the upper airway microbiota of mice administered our representative commensal 9 
consortia was dominated by that consortium and colonization by each consortia were similar (Extended 10 
Data Fig. 6b). These data support a model whereby Proteobacteria prime an IL-17A-dependent immune 11 
defence program in the adult upper airway, however, encapsulation allows K. pneumoniae to withstand 12 
these defences to successfully establish colonization.   13 
 14 
Intestinal Bacteroidetes protect against Klebsiella pneumoniae transmission via IL-36 and this 15 
requires the Bacteroidetes commensal colonization factors 16 
 17 
Individuals colonized by K. pneumoniae act as reservoirs for its spread to other hosts within a 18 
population15,16,42,43 which led to our third question: how does the battle between K. pneumoniae and the 19 
microbiota during colonization of different mucosal niches impact its host-to-host spread? To answer 20 
this, first, we investigated the contribution of the upper airway and intestinal reservoirs to K. pneumoniae 21 
transmission. To investigate the role of the upper airway reservoir, neonatal mice (7 – 11 days old) with 22 
established upper airway K. pneumoniae colonization (referred to as “index” mice) were cohoused with 23 
naïve (non-K. pneumoniae colonized) neonatal mice (referred to as “contact” mice) and then to 24 
determine transmission, K. pneumoniae colonization levels in contact animals were quantified. After 4 25 
days of cohousing there was no detectable K. pneumoniae in the upper airway of the contacts 26 
(Extended Data Figure 10, experiment 1). No transmission was observed if the contact mice were 27 
 11 
antibiotic treated or non-antibiotic treated before cohousing (Extended Data Figure 10, experiment 2). 1 
There was, however, limited transmission from the upper airway of neonatal index mice to the intestine 2 
of neonatal contacts (Extended Data Figure 10, experiment 3). This suggests that despite mice not 3 
sneezing there is limited shedding of K. pneumoniae from the upper airway. Similarly to neonates, no 4 
transmission was observed from the upper airway of adult index to the same niche in adult contact 5 
animals (Extended Data Figure 10, experiment 4). We then assessed transmission between intestinal 6 
reservoirs in neonates aged between 7 and 11 days as these animals are not coprophagic44. Cohousing 7 
neonatal index mice with established intestinal colonization with naïve neonatal contacts resulted in 8 
transmission of K. pneumoniae to the intestine of all contacts (Extended Data Figure 10, experiment 9 
5), indicating that in the absence of microbiota-mediated defences, K. pneumoniae transmission occurs 10 
primarily from the intestinal reservoir. We confirmed that the antibiotic resistance profiles of K. 11 
pneumoniae isolated from neonatal contact mice matched the antibiotic resistance profiles of K. 12 
pneumoniae inoculated into index mice (Extended Data Fig. 9a), confirming that the K. pneumoniae 13 
isolated from contact mice originated from the index animals. To understand how the development of 14 
the adult microbiota, which protects against K. pneumoniae colonization in the intestine, impacts 15 
transmission, we used three approaches. Firstly, adult index mice with established intestinal K. 16 
pneumoniae colonization were cohoused with either antibiotic treated, or non-antibiotic treated, contact 17 
mice. Antibiotic treated adult contact animals all acquired K. pneumoniae (Extended Data Figure 10, 18 
experiment 6 and 7), whereas there was limited transmission to non-antibiotic treated adult contact 19 
animals (Extended Data Figure 10, experiments 8 and 9). Again, we confirmed that the antibiotic 20 
resistance profiles of K. pneumoniae isolated from adult contact mice matched the antibiotic resistance 21 
profiles of K. pneumoniae inoculated into index mice (Extended Data Fig. 9b,c), confirming that the K. 22 
pneumoniae isolated from contact mice originated from the index animals. Secondly, we orally 23 
inoculated the protective Bacteroidetes commensals into K. pneumoniae colonized neonatal index mice, 24 
and also naïve neonatal contact mice, prior to cohousing. This was sufficient to block transmission of K. 25 
pneumoniae between hosts (Extended Data Figure 10, experiment 10 and Supplementary Fig. 10a). 26 
To examine whether transmission required direct contact of animals, adult contacts were housed in a 27 
 12 
cage that had previously housed intestinally colonized index mice. Despite all index mice and fecal 1 
material being removed from the cage prior to housing, all contact mice became colonized by K. 2 
pneumoniae (Extended Data Figure 10, experiment 11), demonstrating that transmission does not 3 
require direct contact between animals or coprophagy. Thirdly, we orally inoculated the protective 4 
Bacteroidetes commensals into both K. pneumoniae colonized adult index mice, and naïve antibiotic 5 
treated adult contact mice, prior to cohousing. We found that Bacteroidetes specifically were sufficient 6 
to block transmission of K. pneumoniae between hosts (Extended Data Figure 10, experiments 12-7 
15, and Supplementary Fig. 10b). The inhibitory effect of Bacteroidetes was lost upon disruption of IL-8 
36 signaling or in the absence of the commensal colonization factors (Extended Data Figure 10, 9 
experiments 16-18). Taken together, these data suggest that the protective effect of Bacteroidetes on 10 
K. pneumoniae colonization limits its transmission within a population. We questioned whether the 11 
inhibitory effect of Bacteroidetes on K. pneumoniae transmission was due to Bacteroidetes reducing K. 12 
pneumoniae shedding from the index animals, or by establishing a protective barrier against K. 13 
pneumoniae acquisition in contact animals. To answer this, Bacteroidetes were given to either the K. 14 
pneumoniae colonized index mice only, or the naïve contacts only. We found that both approaches 15 
reduced K. pneumoniae transmission but that introduction of Bacteroidetes to contacts was more 16 
effective than the effect of Bacteroidetes in index mice (Extended Data Figure 10, experiments 19 17 
and 20), demonstrating that the critical point in transmission controlled by Bacteroidetes is fortification 18 
of the immune barrier to prevent K. pneumoniae establishment in a new host. Collectively, our data 19 
show that CCF-producing Bacteroidetes inhibit the spread of K. pneumoniae within a population.  20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 13 
DISCUSSION  1 
 2 
Whilst it has been assumed that colonization resistance is a property common to resident microbial 3 
communities colonizing different host mucosae, whether the rules and mechanisms of colonization 4 
resistance for a given pathogen are shared between different niches is poorly defined45. We reveal that 5 
microbiota development drives separate host defence programs in the adult intestine and upper airway 6 
to inhibit colonization by the K. pneumoniae (Supplementary Fig. 11). This major antibiotic-resistant 7 
pathogen can overcome these defences in the upper airway but cannot compete with the microbiota in 8 
the intestine. Because of this, microbiota dysbiosis within an individual might not only promote K. 9 
pneumoniae colonization in that host but also promotes its spread to others. Thus, the defined 10 
consortium of Bacteroidetes we identify here could provide population level protection against K. 11 
pneumoniae by preventing its transmission between hosts – the ultimate means of infectious disease 12 
control.  13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 14 
ACKNOWLEDGEMENTS 1 
 2 
T.B.C. is a Sir Henry Dale Fellow jointly funded by the Wellcome Trust and Royal Society (Grant Number 3 
107660/Z/15Z). For J.A.K.M. and J.R.M., the Division of Integrative Systems Medicine and Digestive 4 
Disease at Imperial College London receives financial support from the National Institute for Health 5 
Research (NIHR) Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare 6 
NHS Trust and Imperial College London. We would like to thank Dr Abigail Clements (Imperial College 7 
London) for providing K. pneumoniae strains, Gregory Donaldson and Sarkis Mazmanian (California 8 
Institute of Technology) for providing wild-type and ΔCCF B. fragilis and B. vulgatus strains and Rebecca 9 
Brown and Max Larkinson (Imperial College London) for providing macrophages.  10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 15 
COMPETING INTERESTS 1 
 2 
The authors declare no competing interests.  3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 16 
AUTHOR CONTRIBUTIONS 1 
 2 
T.B.C. and R.P.S. conceived and performed all colonization, transmission and immunological 3 
experiments, analysed data, and wrote the manuscript. J.A.K.M. and J.R.M. performed sequencing 4 
experiments, analysed sequencing data and contributed to the manuscript. J.R.M. and T.B.C. acquired 5 
funding. 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 17 
FIGURE LEGENDS 1 
 2 
Figure 1. The adult microbiota protects against colonization by antibiotic-resistant Klebsiella 3 
pneumoniae in the intestine but not upper airway. (a) Experimental scheme for (b-j): “ABX” = 4 
metronidazole, neomycin, vancomycin and ampicillin (MNVA) in drinking water; “Kp” = K. pneumoniae 5 
oral or intranasal inoculation; and “Sample” = upper airway or fecal sampling day. Days relative to K. 6 
pneumoniae inoculation. (b,c) K. pneumoniae (OXA-48) burden in the (b) upper airway (n=8 animals) 7 
or (c) colon of neonatal mice (n=8 animals). (d-f) K. pneumoniae (OXA-48) (n=8 animals) (d), K. 8 
pneumoniae (B5055) (n=8,9 animals) (e), and K. pneumoniae (ST258) (n=7 animals) (f) burden in upper 9 
airways of adult mice. (g-j) K. pneumoniae (OXA-48) (n=6 animals) (g), K. pneumoniae (B5055) (n=8 10 
animals) (h), K. pneumoniae (ST258) (n=7 animals) (i) and K. quasipneumoniae subsp. 11 
similipneumoniae (n=5 animals) (j) fecal burden in adult mice. (k) Experimental scheme for (l,m): “ABX” 12 
= MNVA in drinking water; “MT” = microbiota transfer by oral and intranasal inoculation; “Kp” = K. 13 
pneumoniae oral inoculation; and “Sample” = fecal sampling day. K. pneumoniae (OXA-48) (n=5 14 
animals) (l) and K. pneumoniae (ST258) (n=6 animals) (m) fecal burden in adult mice. Upper airway 15 
colonization data displayed in red and intestinal colonization data in blue. All statistical comparisons 16 
were made by Mann-Whitney test (two-tailed), horizontal lines indicate median values, ND is none 17 
detected (limit of detection for K. pneumoniae in feces = 103 CFU/g). 18 
 19 
Figure 2. Intestinal Bacteroidetes protect against Klebsiella pneumoniae colonization. (a,b) 20 
Relative abundance of bacterial phyla (a) and orders (b) in (adult feces n=5 animals) and large intestine 21 
of neonatal mice (n=6 animals). Each bar represents a single mouse. (c) Experimental scheme for (d-22 
g): “ABX” = MNVA in drinking water; “GF” = germ-free mice; “CC” = commensal consortia inoculation 23 
by oral gavage (see Materials and Methods); “Kp” = K. pneumoniae oral inoculation; and “Sample” = 24 
fecal sampling day. Days relative to K. pneumoniae inoculation. (d-f) K. pneumoniae (OXA-48) (n=7,8 25 
animals) (d), K. pneumoniae (B5055) (n=8 animals) (e), and K. pneumoniae (ST258) (n=7,8 animals) 26 
(f) fecal burden in adult antibiotic treated mice. (g) K. pneumoniae (ST258) fecal burden in germ-free 27 
 18 
mice (n=5 animals). (h) Experimental scheme for (i-k): acronyms as in (c). K. pneumoniae (OXA-48) 1 
(n=5 animals) (i) and K. pneumoniae (ST258) (n=7 animals) (j) fecal burden in adult mice. K. 2 
pneumoniae (ST258) (k) fecal burden in neonatal mice (n=6,7 animals). All statistical comparisons were 3 
made by Kruskal-Wallis test with Dunn’s correction for multiple comparisons. Horizontal lines indicate 4 
median values. 5 
 6 
Figure 3. Bacteroidetes protect against Klebsiella pneumoniae colonization in the intestine 7 
through IL-36 signalling and macrophages. (a) Experimental scheme for (b-e): “ABX” = MNVA in 8 
drinking water; “CC” = commensal consortia oral inoculation; “Kp” = K. pneumoniae oral inoculation; 9 
and “Sample” = fecal sampling day; “Antibody treatment” = antibody, or isotype control, treatment. Days 10 
relative to K. pneumoniae inoculation. (b-e) K. pneumoniae (OXA-48) burden in the feces of adult mice 11 
(n=5,7,8 animals). (e) K. pneumoniae (ST258) burden in the feces of adult mice (n=6 animals). (f) 12 
Experimental scheme for (g-i): acronyms as in (a), days on which recombinant IL-36g was administered 13 
by intraperitoneal injection are indicated. (g,h) K. pneumoniae (OXA-48) burden (n=6,7 animals) (g), 14 
and K. pneumoniae (ST258) burden (n=6 animals) (h) in the feces of adult mice. (i) Intestinal cytokine 15 
levels 3 days after oral inoculation with indicated commensal consortia (n=5 animals). (j) Experimental 16 
plan for (k-n), acronyms in experimental plan as in (a), “Clodronate” = day of clodronate liposome, or 17 
empty liposome treatment. (k,l) K. pneumoniae (OXA-48) burden (n=7,8 animals) (k), and K. 18 
pneumoniae (ST258) burden (n=5,6 animals) (l) in the feces of adult mice. (m) Intestinal cytokine levels 19 
3 days after oral inoculation with indicated commensal consortia (n=5). (n) K. pneumoniae (OXA-48) 20 
fecal burden in adult mice (n=6,7 animals). Statistical comparisons were made by Kruskal–Wallis test 21 
with Dunn’s correction for multiple comparisons (b-e, i-l and n), and by Mann-Whitney test (two-tailed) 22 
(g,h,m). Horizontal lines indicate median values, error bars are standard deviation. 23 
 24 
Figure 4. Bacteroidetes require their commensal colonization factors to protect against 25 
Klebsiella pneumoniae colonization in the intestine. (a) Experimental scheme: “ABX” = MNVA in 26 
drinking water; “CC” = commensal consortia oral inoculation; “Kp” = K. pneumoniae oral inoculation; 27 
 19 
and “Sample” = fecal sampling day. Days relative to K. pneumoniae inoculation. (b) K. pneumoniae 1 
(OXA-48) fecal burden in adult mice (n=5 animals). Mice were orally inoculated with either a consortium 2 
of wild-type or isogenic ΔCCF Bacteroidetes (B. fragilis and B. vulgatus). (d) Bacteroidetes levels in 3 
feces of mice from (b). (d) Intestinal cytokine levels 3 days after oral inoculation of Bacteroidetes 4 
consortia (n=5 animals). (e,f) K. pneumoniae (OXA-48) (n=6 animals) (e) and K. pneumoniae (ST258) 5 
(n=6 animals) (f) fecal burden in adult mice. Indicated mice were orally inoculated with either WT B. 6 
fragilis, ΔCCF B. fragilis or ΔCCF::CCF B. fragilis. (g) Intestinal cytokine levels 3 days after oral 7 
inoculation with either WT B. fragilis, ΔCCF B. fragilis or ΔCCF::CCF B. fragilis (n=5). (h) Mucosal 8 
association of WT B. fragilis, ΔCCF B. fragilis and ΔCCF::CCF B. fragilis (n=5,6 animals). (i) B. fragilis 9 
levels in feces (n=5,6 animals). Statistical comparisons were made by Kruskal–Wallis test with Dunn’s 10 
correction for multiple comparisons (b-c,e-i), and by Student’s t-test (two-tailed) (d). Horizontal lines 11 
indicate median values, error bars are standard deviation. 12 
 13 
Figure 5. Proteobacteria primes upper airway defences through IL-17A but encapsulation allows 14 
Klebsiella pneumoniae to overcome these defences. (a) Experimental scheme for (b): “ABX” = 15 
MNVA in drinking water; “MT” = microbiota transfer; “Kp” = K. pneumoniae intranasal inoculation; and 16 
“Sample” = upper airway lavage sampling; “Dexa” = dexamethasone treatment. Days relative to K. 17 
pneumoniae inoculation. (b) Upper airway K. pneumoniae burden (WT B5055), unencapsulated K. 18 
pneumoniae (∆CPS B5055), and complemented K. pneumoniae (∆CPS::CPS B5055) in adult mice 19 
(n=7,9 animals). (c) Experimental plan for (d-f), acronyms as in (a), “Antibody treatment” = antibody, or 20 
isotype control, treatment. Days relative to K. pneumoniae inoculation. (d-f) K. pneumoniae (WT and 21 
∆CPS B5055) upper airway burden in adult mice (n=5,7,8,9 animals). (g) Experimental scheme for (h): 22 
acronyms as in (a), days of rIL-17A, or vehicle control, administration are indicated. (h) Upper airway 23 
burden of unencapsulated K. pneumoniae (∆CPS B5055), and complemented K. pneumoniae 24 
(∆CPS::CPS B5055) in adult mice (n=6 animals). (i) Experimental plan for (j-m), acronyms in 25 
experimental plan as in (a,c), “CC” = indicated commensal consortia inoculation by intranasal inoculation 26 
 20 
(see Materials and Methods). (j-m) Upper airway K. pneumoniae burden (WT B5055), unencapsulated 1 
K. pneumoniae (∆CPS B5055), and complemented K. pneumoniae (∆CPS::CPS B5055) in adult mice 2 
(n=5,7,8 animals). Mice were antibiotic treated in (j) and (l) and germ-free in (k). Statistical comparisons 3 
were made by Kruskal–Wallis test with Dunn’s correction for multiple comparisons (b,f,h,j-m) and by 4 
Mann-Whitney test (two-tailed) (d,e). Horizontal lines are median values 5 
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MATERIALS AND METHODS 1 
 2 
Bacterial Strains. Bacteria used in this study and their growth conditions are outlined in 3 
Supplementary Table 1. 4 
 5 
PCR amplification and sequencing of wzi gene. To identify the capsule type of the K. pneumoniae 6 
strains used in this study, genomic DNA was isolated from specified K. pneumoniae strains using the 7 
Wizard Genomic DNA purification kit (Promega) as per the manufacturer’s instructions. A 580 bp 8 
segment of the wzi gene was amplified from the genomic DNA by PCR using the wzi primers outlined 9 
in Supplementary Table 246. The 25 µL PCR reaction contained 200 µM dNTPs, 0.5 µM of each primer, 10 
5 µL genomic DNA template, 1 × GC buffer and 0.25 µL Phusion polymerase (New England Biolabs). 11 
The PCR reaction was performed, following denaturation at 94°C for 2 minutes, by running 30 cycles 12 
of: 94°C for 30 seconds; 55°C for 40 seconds; and 72°C for 30 seconds. A final elongation step of 72°C 13 
for 5 minutes ended the reaction. The PCR was run on a 2% TAE agarose gel and the 580 bp band 14 
excised and purified using the Monarch DNA gel extraction kit (New England Biolabs). Sanger 15 
sequencing was performed on both strands using the PCR primers. The resulting consensus sequence 16 
was used to identify its corresponding wzi gene using the capsular typing database 17 
(https://bigsdb.pasteur.fr/klebsiella/klebsiella.html). 18 
 19 
Mice. The use of mice was performed under the authority of the UK Home Office outlined in the Animals 20 
[Scientific Procedures] Act 1986 after ethical review by Imperial College London Animal Welfare and 21 
Ethical Review Body (PPL 70/7969). Wild-type C57BL/6 mice were purchased from Charles River (UK). 22 
Germ-free Swiss Webster mice were purchased from Taconic (Denmark). All adult mice were female 23 
and between 6 − 14 weeks old, except the germ-free mice which were both male and female. Adult mice 24 
were housed no more than five per cage with Aspen chip 2 bedding with a 12 hour light and 12 hour 25 
 22 
dark cycle at 20oC − 22oC. Neonatal mice were 7 – 11 days old. Mice were randomly assigned to 1 
experimental groups, water was provided ad libitum and mice were fed RM1 (Special Diet Services). 2 
 3 
Microbiota-depletion, antibody, inhibitor and recombinant protein treatment. Mice were given 4 
broad-spectrum antibiotics (metronidazole 1 g/L, neomycin sulfate 1 g/L, ampicillin 1 g/L, and 5 
vancomycin 0.5 g/L (MNVA)) in drinking water for 7 – 14 days as described previously29. For treatment 6 
with a b-lactam and macrolide antibiotic combination, mice were given a total of four doses of 7 
azithromycin (10 mg/kg/dose) and cefotaxime (40 mg/kg/dose) by intraperitoneal injection 1 and 2 days 8 
prior to K. pneumoniae inoculation. Infant mice were indirectly exposed to antibiotics through their dams. 9 
Dams were given the MNVA antibiotic cocktail in their drinking water as in47. Indicated groups of mice 10 
were treated with dexamethasone (5 mg/kg/dose) (Sigma). Anti-IL-17A (R&D Systems), anti-IL-36R 11 
(Invitrogen), anti-IFNg (Abcam), and isotype control were administered at timepoints indicated in figures 12 
prior to oral inoculation of K. pneumoniae via the intraperitoneal route at 75 μg/mouse to disrupt cytokine 13 
signalling. Neutrophils were depleted using the anti-mouse Ly-6G antibody (1A8) (Biolegend). 14 
Recombinant IL-17A (R&D Systems) and recombinant IL-36g (R&D Systems) (10 μg/mouse) were 15 
administered at timepoints indicated in figures prior to oral inoculation of K. pneumoniae with inoculation 16 
via the intraperitoneal route. Macrophages were depleted using clodronate containing liposomes as 17 
described previously48. 18 
 19 
Models of bacterial colonization, quantification of bacterial load in the upper airway and 20 
intestine. For upper airway colonization of K. pneumoniae in adult mice, unanaesthetized animals were 21 
intranasally administered indicated bacteria in 20 μL. In neonates, unanaesthetized animals were 22 
intranasally administered K. pneumoniae in 5 μL. To establish intestinal colonization in adults, 23 
unanaesthetized animals were orally inoculated with K. pneumoniae (5´105 CFU) in approximately 200 24 
µL. For all experiments K. pneumoniae was grown to mid-log phase and resuspended in sterile PBS for 25 
inoculation. Microbiota transfer was carried out as described in29, 3 days prior to inoculation with K. 26 
pneumoniae. Quantification of commensal bacterial load in the upper airway and intestine was carried 27 
 23 
out essentially as described in29. For 16s rRNA analysis of consortia engraftment, we used primers 1 
outlined in Supplementary Table 2 (see Microbiome sequencing). To quantify Klebsiella in the upper 2 
airway and intestine, Klebsiella ChromoSelect Selective Agar Base (Sigma) and for b-lactamase-3 
producing Klebsiella, ESBL ChromoSelect Agar Base (Sigma) were used as per the manufacturer’s 4 
instructions. We confirmed that the coloured colonies on these chromogenic plates were Klebsiella by 5 
16s rRNA sequencing. For consortia inoculation mice were orally inoculated 5´108 CFU of either of the 6 
following: the intestinal Bacteroidetes consortium consisted of: B. fragilis, B. caccae, B. 7 
thetaiotaomicron, B. uniformis, B.ovatus; the intestinal Firmicutes consortium: C. ramosum, C. 8 
symbiosum, C. orbiscindens, C. histolyticum, E. faecalis; the intestinal Actinobacteria consortium: B. 9 
adolescentis, E. lenta, B. breve; and the intestinal Proteobacteria consortium: E. coli, C. koseri, A. 10 
radioresistens. For all experiments using consortia of intestinal commensals, bacteria were grown to 11 
mid-log phase. For anaerobic consortia (Firmicutes, Bacteroidetes, and Actinobacteria) bacteria were 12 
resuspended in pre-reduced sterile PBS prior to inoculation, and for aerobic consortia (Proteobacteria) 13 
bacteria were resuspended in sterile PBS prior to inoculation. For upper airway consortia inoculation 14 
unanaesthetized animals mice were intranasally inoculated 1´106 CFU of either of the following in 20 15 
µL: the upper airway Bacteroidetes consortium consisted of: P. nigrescens and P. melaninogenica; the 16 
upper airway Firmicutes consortium: S. epidermidis and L. crispatus; the upper airway Actinobacteria 17 
consortium: P. acnes and C. propinquum; and the upper airway Proteobacteria consortium: H. 18 
influenzae and M. catarrhalis. For all experiments using consortia of upper airway commensals, bacteria 19 
were grown to mid-log phase and consortia were resuspended in sterile PBS prior to inoculation. 20 
Because of the small inoculation volume and lack of anesthesia these bacteria remain in the upper 21 
airway29. 22 
 23 
Cytokine measurements. Cytokine levels were determined using ELISA kits for TNFa, IL-17A, IFNg 24 
(Biolegend) and IL-36g (antibodies-online.com) according to the manufacturer’s instructions. 25 
 26 
 24 
Macrophage culture and killing assay. Authenticated J774A.1 macrophages (Sigma-Aldrich) were 1 
cultured in DMEM supplemented with 10% v/v FBS, penicillin (100 units/mL) and streptomycin (100 2 
mg/mL) and maintained at 37oC and 5% (v/v) CO2. This cell line was free of mycoplasma contamination. 3 
For bone marrow-derived macrophages, bone marrow was harvested from the femurs and tibiae of 4 
C57BL/6 mice and differentiated into macrophages by culturing in R10 medium containing 15% L-cell 5 
conditioned media and maintained at 37oC and 5% (v/v) CO2. Macrophage killing assays were carried 6 
out essentially as described before29,49. 7 
 8 
Microbiome sequencing. For DNA extraction from feces, lung and upper airway lavage fluid DNA 9 
extracted using the E.Z.N.A Stool DNA kit (Omega Bio-Tek) as per the manufacturer’s instructions. 10 
Homogenization of the stool and lung was accomplished by bead disruption with approximately 200 mg 11 
beads using a FastPrep-24 instrument (MP Biomedicals) by 15 repeated pulses of 20 seconds vortexing 12 
and a subsequent 2 minute recovery. All samples were vortexed for 30 seconds to ensure complete 13 
disruption before proceeding with the protocol. Processing included the optional extra steps of 14 
incubating at 95oC to ensure sufficient lysis of Gram-positive bacteria, and treatment with 100 µg of 15 
RNase A for 3 minutes at 37oC to remove unwanted RNA. For quantification of mucosa-associated 16 
bacteria, mucus was scraped from intestine that had been washed with sterile PBS to remove all fecal 17 
matter, as described in31 and DNA extracted by bead beating as above. Extracted DNA was then used 18 
for 16s rRNA gene qPCR and deep sequencing. For qPCR, in a total 10 μL reaction there was 1 × SYBR 19 
Green PCR Master Mix (Thermo Fisher Scientific), 200 nM of each forward and reverse primer 20 
(Supplementary Table 2), and 2 μL template DNA. qPCR was performed on an Applied Biosystems 21 
StepOnePlus instrument and cycled 40 times with 15 seconds at 95 °C and 1 min at 61oC. To calculate 22 
16s rRNA gene copy numbers, a standard curve was generated using plasmids containing a cloned 16s 23 
rRNA gene from a representative bacterial species of the indicated phylum (Supplementary Table 2). 24 
Plasmid copy numbers were calculated using the formula: (amount of plasmid in ng × 6.0221 × 1023 25 
molecules/mol)/((4500 × 660 g/mol) × 1 × 109 ng/g), where 4500 is the estimated length of the plasmid 26 
with the 16s rRNA gene insert and 660 g/mol is the average mass of 1 base of dsDNA. Using this 27 
 25 
standard curve, 16s rRNA gene copy number per gram of stool was determined. 16s rRNA gene 1 
sequencing sample libraries were generated using Illumina’s 16s Metagenomic Sequencing Library 2 
Preparation Protocol with some modifications. The V1-V2 16s rRNA gene regions were amplified from 3 
stool isolated DNA using primers at a ratio as described previously 50. Index PCR reactions were cleaned 4 
and subsequently normalized with the SequalPrep Normalization Plate Kit (Life Technologies). These 5 
libraries were quantified by the NEBNext Library Quant Kit for Illumina (New England Biolabs). 6 
Sequencing data was generated using the MiSeq Reagent Kit v3 (Illumina) and paired-end 300 bp 7 
chemistry on an Illumina MiSeq platform (Illumina Inc). Sequencing data was processed following the 8 
DADA2 pipeline as previously described51. The SILVA bacterial database version 132 was used to 9 
classify the sequence variants (www.arb-silva.de/).  10 
 11 
Models of bacterial transmission. For transmission studies in adult mice, “index” mice colonized by 12 
K. pneumoniae either in the upper airway or intestine were cohoused with naïve “contact” mice at 13 
indicated “index”:”contact” ratios. “Contact” mice were either treated with azithromycin and cefotaxime 14 
as above, or non-antibiotic treated as indicated. To study K. pneumoniae transmission in infant mice, a 15 
single infant “index” mouse was colonized by K. pneumoniae in the intestine and returned to its litter of 16 
naïve “contact” littermates. To determine whether direct contact between animals was required for 17 
transmission, indicated naïve contact mice were housed in a cage which had previously housed K. 18 
pneumoniae colonized “index” mice. Before the addition of the “contact” animals, all feces was removed 19 
from the cage.  20 
 21 
Statistical and reproducibility. Statistical comparisons were performed using GraphPad Prism 8 22 
software. To compare differences between two groups, the Student’s t-test or the Mann–Whitney test 23 
were used as appropriate (two-tailed). For statistical analysis of transmission, Fisher’s exact test was 24 
used (two-sided). For multiple comparisons, a Kruskal–Wallis test with Dunn’s correction for multiple 25 
comparisons was used. All error bars indicated standard deviation. All experiments were from a 26 
minimum of 4 biological replicates, with data from all replicates included in statistical analysis and no 27 
 26 
data excluded. Animals were randomly assigned to groups (cages) prior to any experimentation. 1 
Differences between litters of mouse pups were controlled for by mixing pups from different litters into 2 
each treatment condition. We used power analysis from published studies and our preliminary 3 
experiments to determine the minimum required sample size required for the groups used in our 4 
experiments. Microbiota sample preparation and analysis performed in a blinded manner.  5 
 6 
Data availability. Microbiome sequencing data have been deposited at the NCBI SRA (BioProject 7 
PRJNA579139). The data supporting the findings of the study are available in this article (see Source 8 
Data) and its Supplementary Information files, or from the corresponding author upon request. 9 
 10 
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Figure 2.  
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Figure 3.  
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Figure 4.  
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Figure 5.  
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Extended Data Figure 1 
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Extended Data Figure 2. 
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Extended Data Figure 3.  
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Extended Data Figure 4. 
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Extended Data Figure 5.  
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Extended Data Figure 6.  
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Extended Data Figure 7.  
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Extended Data Figure 8.  
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Extended Data Figure 9.  
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Extended Data Figure 10.  
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Supplementary Figure 1. Supplementary Figure 1. Antibiotics deplete the microbiota in 
neonatal and adult mice. (a,b) Levels of commensal bacteria the feces (n=5 animals) and 
upper airway (n=5 animals) of neonatal mice measured by total 16s rRNA gene copies. (c) 
Levels of commensal bacteria in the upper airway of adult mice (n=5 animals) measured by 
total 16s rRNA gene copies. (d,e) Levels of commensal bacteria  in feces of adult mice (n=5 
animals) measured by 16s rRNA gene copies (total bacteria, Firmicutes, and Bacteroidetes). 
Antibiotics were MNVA (a-d) and azithromycin and cefotaxime (e). Statistical comparisons 
were by Mann-Whitney (two-tailed), horizontal lines indicate median values. 
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Supplementary Figure 2. . Validation of upper airway colonization by K. pneumoniae. 
Burden of K. pneumoniae (WT B5055) in adult mice at indicated sites 1 day post-intranasal 
inoculation (n=5 animals). Mice were intranasally inoculated 5´105 CFU. Horizontal lines 
indicate median values. 
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Supplementary Figure 3. . Clinically relevant antibiotic regimens promote intestinal 
colonization by K. pneumoniae. (a,b) K. pneumoniae (OXA-48) (a), K. pneumoniae (B5055) 
and (b) fecal burden in adult mice. Antibiotics were azithromycin and cefotaxime. Days 
indicated are post-inoculation with K. pneumoniae, ND is none detected (the limit of detection 
for K. pneumoniae in feces = 103 CFU/g) and horizontal lines indicate median values. 
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Supplementary Figure 4. Colonization of the upper airway or intestine does not promote 
weight loss. (a,b) Change in weight of mice colonized by indicated Klebsiella (K. pneumoniae 
OXA-48, B5055, ST258 or K. quasipneumoniae subsp. similipneumoniae) in the upper airway 
(A) and intestine (B) (n=7 animals). Indicated days are post-K. pneumoniae inoculation, error 
bars are standard deviation. 
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Supplementary Figure 5. Dexamethasone treatment does not cause changes to the 
microbiota preventing it protecting against K. pneumoniae. K. pneumoniae (OXA-48) 
burden in the feces of adult 3 days post-oral inoculation of K. pneumoniae (n=5 animals). 
Microbiota transfer was 3 days prior to oral inoculation of K. pneumoniae (5´105 CFU). 
Statistical comparison was by Mann-Whitney (two-tailed), horizontal lines indicate mean 
values. 
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Supplementary Figure 6. The transition from neonate to adult is accompanied by 
changes in intestinal cytokine production. Change in cytokine level measured by ELISA in 
the intestine from neonate to adult. For each cytokine, from left to right the samples are: 
neonatal (non-antibiotic treated), adult (non-antibiotic treated), and adult (antibiotic treated). 
Antibiotics were MNVA (n=5 animals). Bars represent mean values. 
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Supplementary Figure 7. Clodronate depletes macrophages in the intestine. The 
expression of the macrophage marker F4/80 was measured as in27-30 in the intestinal tissue 
of antibiotic treated mice, antibiotic treated mice administered the Bacteroidetes consortium 
(as in Fig. 2) and clodronate liposomes, and antibiotic treated mice administered the 
Bacteroidetes consortium and empty liposomes (n=5 animals). Statistical comparisons were 
by Kruskal–Wallis test with Dunn’s correction for multiple comparisons, horizontal lines 
indicate median values. 
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Supplementary Figure 8. Neutrophils are not required for Bacteroidetes to protect 
against K. pneumoniae in the intestine. K. pneumoniae (OXA-48) burden in the feces of 
adult mice 2 days post-inoculation (n=5 animals). Bacteroidetes administered as in Fig. 2.  
Antibodies administered 3 and 1 days before Bacteroidetes (100 μg/mouse via intraperitoneal 
injection). Statistical comparison was by Mann-Whitney (two-tailed), horizontal lines indicate 
mean values. 
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Supplementary Figure 9. The transition from neonate to adult is accompanied by 
changes in upper airway cytokine production. Change in cytokine level in the upper airway 
measured by ELISA from neonate to adult. For each cytokine, from left to right the samples 
are: neonatal (non-antibiotic treated), adult (non-antibiotic treated), and adult (antibiotic 
treated). Antibiotics were MNVA (n=5 animals). Bars represent mean values. 
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Supplementary Figure 10. Bacteroidetes protect against K. pneumoniae transmission 
in neonatal and adult mice. (a,b) K. pneumoniae (OXA-48) fecal burden in neonatal (a) and 
adult (b) contact mice after 4 days cohousing (n=5 animals). Indicated groups were 
administered the intestinal Bacteroidetes consortia as in Fig. 2. ND is none detected (the limit 
of detection for K. pneumoniae in feces = 103 CFU/g) and horizontal lines indicate median 
values.  
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Supplementary Figure 11. Proposed model for microbiota programmed immune 
defences against Klebsiella pneumoniae colonization in the upper airway and intestine. 
The maturation of the adult microbiota drives the development of immune defences in the 
upper airway and intestine. In the upper airway Proteobacteria enhance IL-17A mediated 
defences against Klebsiella pneumoniae, whereas in the intestine Bacteroidetes enhance IL-
36 mediated defences against Klebsiella pneumoniae. In the upper airway Klebsiella 
pneumoniae overcomes IL-17A-mediated defences through encapsulation to successfully 
colonize this site. By contrast, Klebsiella pneumoniae is unable to withstand the macrophage 
driven immune defences in the intestine and is block from colonization of this niche. Dysbiosis 
of the microbiota facilitates intestinal colonization by Klebsiella pneumoniae and this is the 
reservoir of transmission between hosts. Thus, the protection provided by intestinal 
Bacteroidetes not only protects an individual host against Klebsiella pneumoniae it also 
protects the whole population by preventing it’s spread between hosts. 
 
 
Bacterium Phylum Growth media Growth conditions 
wzi 
sequence 
type 
Associated 
Capsule 
type 
Bacteroides 
fragilis (WT) Bacteroidetes 
Brain heart 
infusion + 5% 
(v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Bacteroides 
fragilis (∆CCF) Bacteroidetes 
Brain heart 
infusion + 5% 
(v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Bacteroides 
fragilis 
(∆CCF::CCF) 
(complemented 
with the B. fragilis 
CCF operon)  
 
Bacteroidetes 
Brain heart 
infusion + 5% 
(v/v) 
defibrinated 
Sheep’s blood + 
chloramphenicol  
Anaerobic, 
37oC – – 
Bacteroides 
vulgatus (WT) Bacteroidetes 
Brain heart 
infusion + 5% 
(v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Bacteroides 
vulgatus(∆CCF) Bacteroidetes 
Brain heart 
infusion + 5% 
(v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Bacteroides 
caccae Bacteroidetes 
Supplemented 
brain heart 
infusion 
Anaerobic, 
37oC – – 
Bacteroides 
thetaiotaomicron Bacteroidetes 
Brain heart 
infusion + 5% 
(v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Bacteroides 
uniformis Bacteroidetes 
Brain heart 
infusion + 5% 
(v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Bacteroides 
ovatus Bacteroidetes 
Supplemented 
brain heart 
infusion 
Anaerobic, 
37oC – – 
Bacteroides  
dorei Bacteroidetes 
Clostridial 
differential broth 
Anaerobic, 
37oC – – 
Bacteroides  
finegoldi Bacteroidetes Liver broth 
Anaerobic, 
37oC – – 
Prevotella 
nigrescens Bacteroidetes 
Tryptic soy 
broth + 
5% (v/v) 
defibrinated 
Anaerobic, 
37oC – – 
Sheep’s blood 
Prevotella 
melaninogenica Bacteroidetes 
Chopped meat 
media 
Anaerobic, 
37oC – – 
Clostridium 
ramosum Firmicutes 
Brain heart 
infusion 
Anaerobic, 
37oC – – 
Clostridium 
symbiosum Firmicutes 
Tryptic soy 
broth + 
5% (v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Clostridium 
orbiscindens Firmicutes 
Chopped meat 
media 
Anaerobic, 
37oC – – 
Clostridium 
histolyticum Firmicutes 
Tryptic soy 
broth + 
5% (v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Enterococcus 
faecalis Firmicutes 
Brain heart 
infusion 
Anaerobic, 
37oC – – 
Lactobacillus 
reuteri Firmicutes 
DeMan, Rogosa 
and Sharpe 
broth 
Aerobic, 
37oC – – 
Lactobacillus 
johnsonii Firmicutes 
DeMan, Rogosa 
and Sharpe 
broth 
Aerobic, 
37oC – – 
Staphylococcus 
epidermidis Firmicutes 
Brain heart 
infusion 
Aerobic, 
37oC – – 
Lactobacillus 
crispatus Firmicutes 
DeMan, Rogosa 
and Sharpe 
broth 
Aerobic, 
37oC – – 
Bifidobacterium 
adolescentis Actinobacteria 
Reinforced 
Clostridial broth 
Anaerobic, 
37oC – – 
Eggerthella lenta Actinobacteria Chopped meat media 
Anaerobic, 
37oC – – 
Bifidobacterium 
breve Actinobacteria 
Tryptic soy 
broth + 
5% (v/v) 
defibrinated 
Sheep’s blood 
Anaerobic, 
37oC – – 
Propionibacterium 
acnes Actinobacteria 
Brain heart 
infusion 
Aerobic, 
37oC – – 
Corynebacterium 
propinquum Actinobacteria 
Brain heart 
infusion 
Aerobic, 
37oC – – 
Escherichia coli Proteobacteria Luria-Bertani (Lennox) broth 
Aerobic, 
37oC – – 
Citrobacter koseri Proteobacteria Brain heart infusion 
Aerobic, 
37oC – – 
Acinetobacter 
radioresistens Proteobacteria 
Tryptic soy 
broth 
Aerobic, 
37oC – – 
Haemophilus 
influenzae Proteobacteria 
Supplemented 
brain heart 
infusion 
Aerobic, 
37oC – – 
Moraxella 
catarrhalis Proteobacteria 
Brain heart 
infusion 
Aerobic, 
37oC – – 
      
K. pneumoniae 
(OXA-48) 
ABX resistance: 
ampicillin (50 
mg/mL), 
azithromycin (50 
mg/mL). 
ABX sensitivity: 
kanamycin (50 
mg/mL) 
Proteobacteria Luria-Bertani (Lennox) broth 
Aerobic, 
37oC 24 K24 
K. pneumoniae 
(ST258) 
ABX resistance: 
ampicillin (50 
mg/mL), 
kanamycin (50 
mg/mL). 
ABX sensitivity: 
gentamycin (50 
mg/mL) 
Proteobacteria Luria-Bertani (Lennox) broth 
Aerobic, 
37oC 154 – 
K. 
quasipneumoniae 
subsp. 
similipneumoniae 
Proteobacteria Luria-Bertani (Lennox) broth 
Aerobic, 
37oC 171 – 
K. pneumoniae 
(WT B5055) Proteobacteria 
Luria-Bertani 
(Lennox) broth 
Aerobic, 
37oC 4 K2 
K. pneumoniae 
(∆CPS B5055) Proteobacteria 
Luria-Bertani 
(Lennox) broth 
Aerobic, 
37oC – – 
K. pneumoniae 
(∆CPS::CPS 
B5055) 
(complemented  
with pGEMT 
containing wza-
wzc) 
Proteobacteria 
Luria-Bertani 
(Lennox) broth 
+ampicillin 
Aerobic, 
37oC – – 
      
 
 
 
 
 
 
 
 
 
 
Supplementary Table  1. Bacteria used in this study. 
Primer Sequence (5’ to 3’) 
Species used as 
a 
template to 
generate 
standard curve 
16s F qRT ACTCCTACGGGAGGCAGCAGT Clostridium 
symbiosum 16s R qRT ATTACCGCGGCTGCTGGC 
Firmicutes F GGAGYATGTGGTTTAATTCGAAGCA Clostridium 
symbiosum Firmicutes R AGCTGACGACAACCATGCAC 
Bacteroidetes F GGARCATGTGGTTTAATTCGATGAT Bacteroides 
uniformis Bacteroidetes R AGCTGACGACAACCATGCAG 
Actinobacteria F TACGGCCGCAAGGCTA Micrococcus 
 luteus Actinobacteria R TCRTCCCCACCTTCCTCCG 
Fusobacteria F AAGCGCGTCTAGGTGGTTATGT Fusobacterium 
necrophorum Fusobacteria R TGTAGTTCCGCTTACCTCTCCAG 
Gammaproteobacteria F TCGTCAGCTCGTGTYGTGA 
E. coli 
Gammaproteobacteria F CGTAAGGGCCATGATG 
B. fragilis F TGATTCCGCATGGTTTCATT 
B. fragilis 
B. fragilis R CGACCCATAGAGCCTTCATC 
wzi F GTGCCGCGAGCGCTTTCTATCTTGGTATTCC N/A 
wzi R GAGAGCCACTGGTTCCAGAATTTCACCGC N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table  2. Primers used in this study. 
